A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Primary Purpose
Hypertension, Plasma Renin Activity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Hydrochlorothiazide
Lisinopril
Amlodipine
metoprolol
lisinopril/hydrochlorothiazide
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg
- Not currently taking BP-lowering medication
- Clinician recommends pharmacologic treatment
- Willing to make necessary study visits
- Able to be contacted by phone
- Has a primary care clinician
- At least 18 years old
Exclusion Criteria:
- Known secondary cause of hypertension
- Pregnancy
- Known diabetes, coronary artery disease or renal disease
- Known sulfonamide allergy or history of gout
- Participant's clinician recommends he/she not enroll
- Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit
- Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg
- Resting heart rate < 55 beats per minute
Sites / Locations
- UNC Chapel Hill
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PRA-guided therapy
Fixed-dose combination treatment-guided therapy
Arm Description
Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
Outcomes
Primary Outcome Measures
Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (<140mmHG systolic and <90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.
Secondary Outcome Measures
Full Information
NCT ID
NCT01658657
First Posted
July 31, 2012
Last Updated
August 17, 2015
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Cornell University, Wake Forest University Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01658657
Brief Title
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Official Title
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
Cornell University, Wake Forest University Health Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Plasma Renin Activity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PRA-guided therapy
Arm Type
Experimental
Arm Description
Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
Arm Title
Fixed-dose combination treatment-guided therapy
Arm Type
Active Comparator
Arm Description
Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide
Intervention Type
Drug
Intervention Name(s)
Lisinopril
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Type
Drug
Intervention Name(s)
metoprolol
Intervention Type
Drug
Intervention Name(s)
lisinopril/hydrochlorothiazide
Intervention Description
This is a combination pill
Primary Outcome Measure Information:
Title
Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
Description
At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (<140mmHG systolic and <90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg
Not currently taking BP-lowering medication
Clinician recommends pharmacologic treatment
Willing to make necessary study visits
Able to be contacted by phone
Has a primary care clinician
At least 18 years old
Exclusion Criteria:
Known secondary cause of hypertension
Pregnancy
Known diabetes, coronary artery disease or renal disease
Known sulfonamide allergy or history of gout
Participant's clinician recommends he/she not enroll
Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit
Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg
Resting heart rate < 55 beats per minute
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Viera, MD, MPH
Organizational Affiliation
Distinguished Associate Professor, Family Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
UNC Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
We'll reach out to this number within 24 hrs